A droplet microfluidics-based platform for generating target-specific, natively-paired immune libraries and identifying potent and developable antibodies
The human antibody repertoire is a promising source for therapeutic-grade antibodies. Yet current methods for strategically mining these B cell repertoires are stymied by throughput and chain pairing considerations. This study presents advancements in fluidics and molecular biology that enable the multi-step encapsulation and capture of B cells from an immunized, humanized mouse in nanoliter sized droplets. Once singularly captured, antigen-specific B-cells can be lysed and individually manipulated via RT-PCR to splice cognate V genes and create a predominantly natively paired library. To explore the importance of these process improvements in library generation, we constructed natively-paired libraries against two therapeutically-relevant human proteins. Through deep sequencing, bioinformatics-driven screening and phage display, we selected functional, target-specific antibodies. Our findings reveal that natively paired libraries contain a higher percentage of target-specific antibodies and demonstrate enhanced potency and improved developability in both in silico and in vitro assessments relative to combinatorial library-derived antibodies. Furthermore, antibodies with native pairing show increased potency as well as improved in silico and in vitro developability compared to their randomly paired counterparts. To this end, we see this droplet microfluidic platform and its capacity to generate and facilitate the high-throughput interrogation of antigen-specific antibody repertoires as an important, orthogonal therapeutic antibody discovery approach.
Authors
- Paula Boutin
- Sagar V. Kathuria (ORCID: https://orcid.org/0000-0003-3670-4467)
- Megan Salemi
- Kayla Keepseagle
- Pep Amengual-Rigo (ORCID: https://orcid.org/0000-0002-3115-0349)
- Norbert Furtmann
- David A. Weitz (ORCID: https://orcid.org/0000-0001-6678-5208)
- John A. Heyman (ORCID: https://orcid.org/0000-0003-0344-3694)
- Anusuya Ramasubramanian (ORCID: https://orcid.org/0000-0001-7178-7734)
- Jocelyn C. Newton
- N.B. Suslov
- Dilyana Dimova (ORCID: https://orcid.org/0000-0003-3876-8974)
- Partha S. Chowdhury (ORCID: https://orcid.org/0000-0003-0990-4658)
- Ankit Mahendra
- Kevin J. Kramer (ORCID: https://orcid.org/0000-0001-8451-9018)
- Kalie A. Mix (ORCID: https://orcid.org/0000-0002-2836-5744)
- Guillaume Mottet (ORCID: https://orcid.org/0000-0002-6575-0748)
- Joern Hopke
- Brendan T. Deveney
- Saleh Riahi
- Hélène Erasimus
- Sambasiva Rao Pemmaraju
- Sarah A. Clark
- Leighton Marcovici
- Taotao Lao
Institutions
- Johnson & Johnson (United States) (US)
- Sanofi (France) (FR)
- Springhouse (US)
- Groupe d’Étude de la Matière Condensée (FR)
- Dana-Farber Cancer Institute (US)
- NKT Therapeutics (United States) (US)
- Dana-Farber/Harvard Cancer Center (US)
- Instituto Brasileiro de Museus (BR)
- Takeda (United States) (US)
- Arc of the United States (US)
- Xilio Therapeutics (United States) (US)
- Sea Education Association (US)
Publication Details
- Journal
- Scientific Reports
- Published
- 2026-01-03
- DOI
- https://doi.org/10.1038/s41598-025-33040-4
- Primary Topic
- Monoclonal and Polyclonal Antibodies Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00